GeneDx is trading 4.1% down at $60.77 as investors continue to digest the impact of ongoing securities fraud class action lawsuits tied to the Fabric Genomics acquisition.
- The litigation follows a prior 49% single-day stock crash, with multiple law firms now actively promoting the case to potential claimants.
- Legal and credibility concerns remain a key overhang on the shares ahead of the August 3, 2026, lead-plaintiff deadline.
- The downward movement persists despite a relatively flat broader market.